ChromaDex Licenses Exclusive Worldwide Patent Rights from the University of Mississippi for Microalgae Technology Targeting Immune Support

IRVINE, Calif., Dec. 2, 2014 /PRNewswire/ — ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today it has licensed exclusive worldwide rights from the University of Mississippi for several patents related to the isolation and use of immunostimulatory extracts from microalgae. The exclusive worldwide license covers U.S. Patent numbers 7,205,284 and 7,846,452.

ChromaDex plans to create a branded ingredient technology that will be formally introduced in early 2015 and will target the immune support and sport nutrition markets. The supply chain is already in place and supporting safety and clinical studies have been completed.

Following its launch, this will be the fifth branded patented ingredient technology developed by ChromaDex, joining NIAGEN™, PURENERGY®, pTeroPure® and ProC3G®. ChromaDex’s ingredient technologies business benefits from its unique business model whereby discovery of new ingredient technologies is often the result of information gathered by its other business units: natural product fine chemicals (known as “phytochemicals”); chemistry and analytical testing services; and subsidiary Spherix Consulting’s product regulatory and safety consulting business.

The licensed technology covers patented and proprietary preparations from food-grade microalgae that are rich in compounds that activate innate immune cells. The predominant active compounds, Braun-type lipoproteins, are potentially useful for improving human immune function. These lipoproteins within Spirulina platensis, Haematococcus pluvialis, Chlorella pyrenoidosa and Aphanizomenon flos-aquae are present at much greater levels than those found within commonly used immune enhancing botanicals, such as Echinacea and ginseng.

Frank Jaksch, CEO and Founder of ChromaDex, stated: “There is a very large existing market for immune support products and the acquisition of this patented technology will enable us to provide a new, science-backed ingredient option for our customers. We are proud to continue to build on our long-standing relationship with the University of Mississippi.”

“ChromaDex is a valued partner of the University of Mississippi and has successfully commercialized other technologies from our School of Pharmacy and the National Center for Natural Products Research,” stated Walt Chambliss, UM director of technology management.  “I am confident that ChromaDex will maximize the potential for this patented extract to benefit consumer health.”

About the University of Mississippi:

The University of Mississippi, the flagship university for the state of Mississippi, opened in 1848. It offers nationally recognized programs across a broad range of undergraduate and graduate studies, from medicine and law to creative writing and accountancy. With more than 23,000 students, Ole Miss is the state’s largest university, and the Chronicle of Higher Education named it as the nation’s 13th-fastest growing university in its Almanac of Higher Education 2014. The university has a diverse student body (23.8 percent of students are ethnic minorities) representing all 50 states and 92 countries. It has been ranked as one of America’s best college values by Kiplinger’s Personal Finance and one of the best places to work by the Chronicle of Higher Education.


View original article at: ChromaDex Licenses Exclusive Worldwide Patent Rights from the University of Mississippi for Microalgae Technology Targeting Immune Support


Leave a Reply